# Biologic Overview 

Sara Treat

---

## Background
-	"-cept" refers to fusion of a receptor to the Fc part of human immunoglobulin G1 (IgG1)
-	"-mab" indicates a monoclonal antibody (mAb)
-	"-ximab" indicates a chimeric mAb
-	"-zumab" indicates a humanized mAb
-	"-umab" indicates a fully human mAb
-	“-tinib” indicates a tyrosine kinase inhibitor (small molecule inhibitors, not true biologics)

## B-cell depletion and inhibition

<table border="1">
  <tr>
    <th>Generic Name (Brand Name)</th>
    <th>Mechanism of Action</th>
    <th>Common Uses</th>
    <th>Common Side Effects</th>
  </tr>
  <tr>
    <td>Belimumab<br>(Benlysta)</td>
    <td>IgG1-lambda mAb that prevents survival of B-lymphocytes by blocking the binding of soluble human B lymphocyte stimulator protein (BLyS) to receptors on B lymphocytes</td>
    <td>lupus nephritis, SLE</td>
    <td>GI symptoms, hypersensitivity reaction, infections, psychiatric disturbances</td>
  </tr>
  <tr>
    <td>Rituximab<br>(Rituxan)</td>
    <td>mAb against CD20 antigen on surface of B-cells; B cell depletion via ab-dependent cell mediated cytotoxicity function of NK cells</td>
    <td>CLL, Non-Hodgkin lymphomas, GPA, microscopic polyangiitis, pemphigus vulgaris, RA; many off-label uses (GvHD, lupus nephritis, MG, neuromyelitis optica)</td>
    <td>Hypogammaglobulinemia, (may be persistent), infusion reaction, HTN, peripheral edema, night sweats, fever, weight gain, angioedema, arthralgias, increased ALT, hypophosphatemia, hematologic abnormalities</td>
  </tr>
</table>

## Complement Inhibition

<table border="1">
  <tr>
    <th>Generic Name (Brand Name)</th>
    <th>Mechanism of Action</th>
    <th>Common Uses</th>
    <th>Common Side Effects</th>
  </tr>
  <tr>
    <td>Avacopan<br>(Tavneos)</td>
    <td>Complement 5a receptor antagonist</td>
    <td>ANCA vasculitis</td>
    <td>HTN, HA, rash, GI upset/diarrhea, hepatotoxicity</td>
  </tr>
</table>

## Costimulation Blockade

<table border="1">
  <tr>
    <th>Generic Name (Brand Name)</th>
    <th>Mechanism of Action</th>
    <th>Common Uses</th>
    <th>Common Side Effects</th>
  </tr>
  <tr>
    <td>Abatacept<br>(Orencia)</td>
    <td>Inhibits T-cell activation by binding CD80 and CD86 on APCs, thus blocking the required CD28 interaction between APCs and T cells.</td>
    <td>RA, psoriasis, JIA</td>
    <td>Nausea, UTI, HA, URI, Antibody development</td>
  </tr>
</table>

## IL-1 Inhibition

<table border="1">
  <tr>
    <th>Generic Name (Brand Name)</th>
    <th>Mechanism of Action</th>
    <th>Common Uses</th>
    <th>Common Side Effects</th>
  </tr>
  <tr>
    <td>Anakinra<br>(Kineret)</td>
    <td>IL-1 receptor antagonist</td>
    <td>IL-1 receptor antagonist deficiency, gout flares, FMF, HLH</td>
    <td>HA, vomiting, infections, nasopharyngitis, Antibody development; in RA: eosinophilia, decreased WBC</td>
  </tr>
  <tr>
    <td>Canakinumab<br>(Ilaris)</td>
    <td>mAb against IL-1β</td>
    <td>Adult onset Still’s disease, Cryoporin-associated periodic syndromes (CAPS), FMF, hyperimmunoglobin D syndrome, TRAPS; off-label: gout flare</td>
    <td>Weight gain, GI sx, HA, vertigo, serious infections</td>
  </tr>
  <tr>
    <td>Rilonacept<br>(Arcalyst)</td>
    <td>IL-β soluble decoy receptor</td>
    <td>Cryoporin-associated periodic syndrome, deficiency IL-1 receptor antagonist, pericarditis</td>
    <td>Antibody development, infection (including serious infection), local site reaction, URI</td>
  </tr>
</table>

## IL-5 Inhibition

<table border="1">
  <tr>
    <th>Generic Name (Brand Name)</th>
    <th>Mechanism of Action</th>
    <th>Common Uses</th>
    <th>Common Side Effects</th>
  </tr>
  <tr>
    <td>Mepolizumab (Nucala)</td>
    <td>mAb against IL-5, direct IL-5 antagonist</td>
    <td>Eosinophilic asthma, EGPA, hypereosinophilic syndromes, rhinosinusitis with nasal polyps</td>
    <td>Local injection site reaction, HA</td>
  </tr>
</table>

## IL-6 Inhibition

<table border="1">
  <tr>
    <th>Generic Name (Brand Name)</th>
    <th>Mechanism of Action</th>
    <th>Common Uses</th>
    <th>Common Side Effects</th>
  </tr>
  <tr>
    <td>Tocilizumab<br>(Actemra)</td>
    <td>IL-6 receptor antagonist</td>
    <td>GCA, RA, JIA, neuromyelitis optica, systemic sclerosis, ILD, cytokine release syndrome for CAR T cells</td>
    <td>Increased serum cholesterol, increased AST/ALT, infusion reaction, HSV infection (&lt;2%)</td>
  </tr>
  <tr>
    <td>Sarilumab<br>(Kevzara)</td>
    <td>IL-6 receptor antagonist (soluble + membrane-bound)</td>
    <td>RA</td>
    <td>Increased AST/ALT, HSV infection (&lt;2%)</td>
  </tr>
</table>

## IL-12/23 Inhibition

<table border="1">
  <tr>
    <th>Generic Name (Brand Name)</th>
    <th>Mechanism of Action</th>
    <th>Common Uses</th>
    <th>Common Side Effects</th>
  </tr>
  <tr>
    <td>Guselkumab<br>(Tremfya)</td>
    <td>Human IgG1 mAb against IL-23</td>
    <td>Psoriasis</td>
    <td>Upper respiratory tract infection (URI), tinea, gastrointestinal symptoms (GI sx)</td>
  </tr>
  <tr>
    <td>Risankizumab<br>(Skyrizi)</td>
    <td>mAb against IL-23 via p19</td>
    <td>IBD, psoriasis, JIA</td>
    <td>Nausea, urinary tract infection (UTI), headache (HA), URI, Antibody development</td>
  </tr>
  <tr>
    <td>Ustekinumab<br>(Stelara)</td>
    <td>mAb against IL-12 + IL-23</td>
    <td>IBD, psoriasis</td>
    <td>Nasopharyngitis, Antibody development, acne vulgaris, gastrointestinal symptoms (GI sx), genitourinary symptoms (GU sx)</td>
  </tr>
</table>

## IL-17 Inhibition

<table border="1">
  <tr>
    <th>Generic Name (Brand Name)</th>
    <th>Mechanism of Action</th>
    <th>Common Uses</th>
    <th>Common Side Effects</th>
  </tr>
  <tr>
    <td>Brodalumab<br>(Siliq)</td>
    <td>Human IgG1 mAb against IL-17A</td>
    <td>Psoriasis</td>
    <td>Infection, tinea, gastrointestinal (GI) issues, suicidal ideation and behavior (REMS program)</td>
  </tr>
  <tr>
    <td>Ixekizumab<br>(Taltz)</td>
    <td>Human IgG4 mAb against IL-17A</td>
    <td>Ankylosing spondylitis (AS), psoriasis</td>
    <td>Infection, tinea, neutropenia, Antibody development, upper respiratory tract infection (URI), Crohn’s disease (<1%)</td>
  </tr>
  <tr>
    <td>Secukinumab<br>(Cosentyx)</td>
    <td>Human IgG1 mAb against IL-17A</td>
    <td>AS, psoriasis</td>
    <td>Nasopharyngitis, GI issues, inflammatory bowel disease (IBD) (<1%)</td>
  </tr>
</table>

## Kinase Inhibition

BLACK BOX warning for mortality, increased malignancies, thrombosis (DVT and PE), and increased cardiovascular events. Data is from tofacitinib, but warning is applied to all JAK inhibitors.

<table border="1">
  <tr>
    <th>Generic Name (Brand Name)</th>
    <th>Mechanism of Action</th>
    <th>Common Uses</th>
    <th>Common Side Effects</th>
  </tr>
  <tr>
    <td>Abrocitinib<br>(Cibinqo)</td>
    <td>JAK-1 inhibitor</td>
    <td>Atopic dermatitis</td>
    <td>Nausea, infections, nasopharyngitis</td>
  </tr>
  <tr>
    <td>Baracitinib<br>(Olumiant)</td>
    <td>JAK-1 and JAK-2 inhibitor</td>
    <td>RA, alopecia areata, off-label: COVID-19</td>
    <td>Upper respiratory tract infection (URI), nausea, increased AST/ALT; less than 1% lymphoma</td>
  </tr>
  <tr>
    <td>Ruxolitinib<br>(Jakafi)</td>
    <td>JAK-1 and JAK-2 inhibitor</td>
    <td>Topical: atopic dermatitis and vitiligo<br>Oral: GvHD, polycythemia vera, myelofibrosis</td>
    <td>Hypertension (HTN), hyperlipidemia (HLD), gastrointestinal (GI) upset, increased liver function tests (LFTs), anemia, infection, dizziness, muscle spasm, fever</td>
  </tr>
  <tr>
    <td>Tofacitinib<br>(Xeljanz)</td>
    <td>JAK-1 and JAK-3 inhibitor</td>
    <td>RA, UC, JIA, psoriatic arthritis</td>
    <td>Nasopharyngitis, skin rash, GI symptoms, genitourinary (GU) symptoms; less than 1% lymphoma</td>
  </tr>
  <tr>
    <td>Upadacitinib<br>(Rinvoq)</td>
    <td>Non-specific JAK inhibitor</td>
    <td>RA</td>
    <td>Upper respiratory tract infection (URI), nausea, neutropenia, increased AST, increased CPK</td>
  </tr>
</table>

## TNF Inhibition

<table border="1">
  <tr>
    <th>Generic Name (Brand Name)</th>
    <th>Mechanism of Action</th>
    <th>Common Uses</th>
    <th>Common Side Effects</th>
  </tr>
  <tr>
    <td>Adalilumab<br>(Humira)</td>
    <td>mAb against TNFα</td>
    <td>RA, IBD, AS, psoriasis, uveitis, hidradenitis suppurativa</td>
    <td>Infection (especially mycobacterial and fungal), drug-induced lupus, skin rash, headache, upper respiratory tract infection (URI), increased creatine phosphokinase (CPK), positive antinuclear antibody (ANA) titer (12%), Antibody development (3-26%)</td>
  </tr>
  <tr>
    <td>Certolizumab<br>(Cimzia)</td>
    <td>Humanized mAb Fab fragment against TNFα</td>
    <td>RA, Crohn’s, AS, psoriasis; *approved for pregnancy</td>
    <td>Skin rash, nausea, URI</td>
  </tr>
  <tr>
    <td>Etanercept<br>(Enbrel)</td>
    <td>TNF receptor linked to Fc portion of IgG1 binds TNF</td>
    <td>RA, AS, psoriasis, JIA</td>
    <td>Skin rash, diarrhea, positive ANA titer (11%)</td>
  </tr>
  <tr>
    <td>Golimumab<br>(Simponi)</td>
    <td>mAb against TNFα</td>
    <td>RA, UC, AS, psoriasis, JIA</td>
    <td>URI, Antibody development (16-38%), positive ANA titer (4-17%)</td>
  </tr>
  <tr>
    <td>Infliximab<br>(Remicade)</td>
    <td>Chimeric mAb against TNFα</td>
    <td>RA, IBD, AS, psoriasis</td>
    <td>Abdominal pain, URI symptoms, anemia, increased ALT, Antibody development (10-50%)</td>
  </tr>
</table>
